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Posttraumatic stress disorder (PTSD) is a stressor-related disorder that develops in a subset of 
individuals exposed to a traumatic experience. Factors associated with vulnerability to PTSD are still 
not fully understood. PTSD is frequently comorbid with various psychiatric and somatic disorders, 
moderate response to treatment and remission rates. The term “theranostics” combines diagnosis, 
prognosis, and therapy and offers targeted therapy based on specific analyses. Theranostics, combined 
with novel techniques and approaches called “omics”, which integrate genomics, transcriptomic, 
proteomics and metabolomics, might improve knowledge about biological underpinning of PTSD, and 
offer novel therapeutic strategies. The focus of this review is on metabolomic and glycomic data in 
PTSD. Metabolomics evaluates changes in the metabolome of an organism by exploring the set of small 
molecules (metabolites), while glycomics studies the glycome, a complete repertoire of glycan 
structures with their functional roles in biological systems. Both metabolome and glycome reflect the 
physiological and pathological conditions in individuals. Only a few studies evaluated metabolic and 
glycomic changes in patients with PTSD. The metabolomics studies in PTSD patients uncovered 
different metabolites that might be associated with psychopathological alterations in PTSD. The 
glycomics study in PTSD patients determined nine N-glycan structures and found accelerated and 
premature aging in traumatized subjects and subjects with PTSD based on a GlycoAge index. Therefore, 
further larger studies and replications are needed. Better understanding of the biological basis of PTSD, 
including metabolomic and glycomic data, and their integration with other “omics” approaches, might 
identify new molecular targets and might provide improved therapeutic approaches.
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Posttraumatic stress disorder (PTSD) is a trauma- and stressor-related disorder (APA, 2013) that 
requires direct or indirect exposure to a single traumatic event or prolonged exposure to stressful 
events. Such events may include witnessing or confrontation with a traumatic event that happened to 
a family member or a close friend, and even exposure to the consequences of traumatic events in some 
professions where exposure is common (Pai et al., 2017). Exposure to a traumatic experience involves 
serious injury, intense fear, actual or threatened death, horror and helplessness (Bisson, 2007; Yehuda, 
2002). The majority of people are likely to be exposed to potentially traumatic events during their 
lifetime; however, rates of exposure differ among different populations (Kessler et al., 2017; Liu et al., 
2017), and development of PTSD is significantly influenced by the type of the traumatic exposure. The 
traumatic experience most frequently leading to a high risk of PTSD is interpersonal violence (i.e. rape), 
while the unexpected death of a loved one is associated with a low risk of PTSD (Kessler et al., 2017). 
The proposed risk factors for PTSD are family and social status, female gender, severity, duration and 
number of traumatic incidents, childhood abuse and neglect, lack of family and social support, as well 
as a history of mental illness (Bisson, 2007; Karatzias et al., 2017; Nedic Erjavec et al., 2018; Zoladz and 
Diamond, 2013).
1.2.Resilience and vulnerability to develop PTSD
PTSD, as a multifactorial and polygenic disorder that shares genetic risk with other psychiatric disorders 
(Solovieff et al., 2014; Ryan et al., 2016; Duncan et al., 2018; Nievergelt et al., 2018), induces great 
suffering in patients and their families and carries enormous public health, social, and economic 
burden to society (Davidson, 2000). Traumatic experience has a major impact on an organism and its 
cellular, molecular, structural and biochemical systems (Girgenti et al., 2017; Michopoulos et al., 2015; 
Nedic Erjavec et al., 2018). However, not all individuals exposed to a traumatic event develop PTSD, 
and the extent to which individuals are vulnerable or resilient to PTSD depends on a variety of 
biological, genetic, and epigenetic factors (Domschke, 2012; Dulka et al., 2017; Duncan et al., 2018; 
Ryan et al., 2016; Schmidt et al., 2011), and the interaction between them. Resilience is a process of 
positive adaptation to particular environmental stress, tragedy, trauma, or adversity, developed 
through complex interaction of genetic, epigenetic, environmental and neurochemical factors (Li et al., 
2017). Resilience or vulnerability to develop PTSD after traumatic exposure differs significantly among 
exposed individuals (Michopoulos et al., 2015), and therefore the prevalence of PTSD is considerably 
lower than exposure to traumas (Bisson et al., 2005). It has been estimated that the lifetime prevalence 
of PTSD ranges from 1.3% to 8.8% (Atwoli et al., 2015). However, combat and war-related traumas are 
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associated with much higher prevalence of PTSD, ranging from 10.1-30.9% in U.S. veterans (Kang et 
al., 2003; Mellon et al., 2018), and estimated to be 18% in Croatian veterans (Priebe et al., 2010). 
PTSD is rarely an isolated disorder and commonly co-occurs with other psychiatric disorders (Flory, 
2015), but also with different somatic disorders (Britvic et al., 2015; Mellon et al., 2018). PTSD 
interferes with many metabolic pathways causing biological alterations (Michopoulos et al., 2015; Wolf 
et al., 2016a; 2016b; Mellon et al., 2018). Comorbid somatic disorders include cardiovascular, 
dermatological, musculoskeletal, pulmonary diseases (Britvic et al., 2015), immune dysfunction and 
metabolic syndrome (Mellon et al., 2018; Wolf et al., 2016a). Subjects with PTSD have higher 
prevalence of obesity (Kozaric Kovacic et al., 2009), increased risk for neurodegenerative diseases, 
cognitive decline and premature aging (Miller et al., 2014; Wolf et al., 2016a; 2016b). More specifically, 
frequent occurrence of metabolic syndrome in combat-related PTSD is associated with decreased 
cortical thickness and consequently cognitive decline induced by temporal and frontal 
neurodegeneration (Wolf et al., 2016a; 2016b). In addition, PTSD is often characterized with psychotic 
features (Hamner, 2011; Pivac and Kozaric-Kovacic, 2006; Compean and Hamner, this issue), that 
worsen the clinical presentation of PTSD. Novel assessment in International Classification of Diseases, 
11th revision, proposes the distinction between PTSD and complex PTSD (Karatzias et al., 2017). In 
complex PTSD, besides core PTSD symptoms, disturbances in self-organization should be present, 
describing the pervasive psychological disturbances that can follow traumatic exposure (Hyland et al., 
2018). Complex PTSD is often severe and highly debilitating (Karatzias et al., 2017). Patients with 
complex PTSD display significantly higher levels of dissociation, depression, anxiety, borderline 
personality disorder symptoms, suicidal ideation and self-harm (Hyland et al., 2018). In addition, early 
life trauma, as well as multiple and interpersonal traumas, are more frequently associated with 
complex PTSD (Karatzias et al., 2017).
1.3.Treatment of PTSD
The treatment of PTSD includes psychological interventions (APA, 2017) and pharmacotherapy 
(Goodnight et al., this issue). Spontaneous remission rates from PTSD in the absence of treatment vary 
considerably (8-89%), however average remission rates of 44% have been reported (Morina et al., 
2014). Recommendations, such as clinical practice guidelines for the treatment of PTSD in adults, given 
by the American Psychological Association (2017) are cognitive behavioral therapy, cognitive 
processing therapy, cognitive therapy, and prolonged exposure therapy as the first line psychotherapy, 
followed by the use of brief eclectic psychotherapy, eye movement desensitization and reprocessing, 
as well as narrative exposure therapy. Pharmacotherapy of PTSD depends on the treatment goals, such 
as reduction of comorbidity as well as improvement of stress resistance, whereas the response to 
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certain pharmacotherapy is due to individual genetic, epigenetic and experiential characteristics (Kao, 
2015). The most commonly used pharmacotherapy is treatment with selective serotonin reuptake 
inhibitors, such as sertraline, fluoxetine, and paroxetine, which decrease hyper-arousal, fear response, 
and numbing (Kao, 2015; Ravindran and Stein, 2009). In addition to these medications, selective 
serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase 
inhibitors, noradrenergic agents, benzodiazepines and atypical antipsychotics are used in treatment of 
PTSD. These drugs reduce numbing, hyper-arousal, anxiety and depressive symptoms, sleep 
disturbances, irritability, re-experiencing and psychotic symptoms (Ravindran and Stein, 2009). 
However, regarding pharmacotherapy, only fluoxetine, paroxetine, sertraline, and venlafaxine are 
recommended for treatment of PTSD (APA, 2017). 
1.4.Biological findings in PTSD
The focus of this review is on metabolomic and glycomic findings in PTSD. Although this paper is not 
intended to be an exhaustive review of the biology of PTSD (as this topics will be covered in other 
reviews in this issue), patients with PTSD show alterations in different biological systems (higher 
sensitivity of sympathetic nervous system, dysregulated activity of hypothalamic-pituitary-adrenal 
(HPA) and thyroid axis, altered function of the neurotransmitters (norepinephrine, serotonin, 
dopamine) and brain derived neurotropic factor (BDNF), increased and premature aging processes 
shown in shortened telomeres, increased DNA damage, mitochondrial dysfunction and altered values 
of the “GlycoAge test” (Fragkaki et al., 2016; Gautum et al., 2015; Kao, 2015; Karabatsiakis et al., 2015; 
Kovacic Petrovic et al., 2016; Mellon et al., 2018; Moreno-Villanueva et al., 2013; Mouthaan et al., 
2014; Mustapic et al., 2007; Nedic Erjavec et al., 2018; Pivac et al., 2006; 2007; 2012; Ryan et al., 2016; 
Sautter et al., 2003; van Zunden wt al., 2015; Yehuda, 2002; 2006; Yehuda and Seckl, 2011). In addition, 
PTSD is frequently associated with disturbed metabolic pathways (Mellon et al., 2018). Furthermore, 
inflammation is a frequent finding in PTSD, since C-reactive protein (CRP) and pro-inflammatory 
cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), and interleukin 6 (IL-
6) are increased in PTSD (Mellon et al., 2018). Inflammatory markers have even been proposed to be 
used as biomarkers of PTSD (Baker et al., 2012; Michopoulos et al., 2015). While these data point to 
PTSD as a systemic disease, it remains to be evaluated whether immune activation precedes 
development of PTSD after traumatic exposure or is a consequence of PTSD (Mellon et al., 2018). 
Besides altered biological function, genetic data from family association, twin, and genome-wide 
association studies suggest that heritability of PTSD ranges from 30-40% (Almli et al., 2014; Duncan et 
al., 2018). As in other complex mental disorders, a number of genes with small effect sizes contributes 
to the cumulative risk for PTSD (covered by Ressler et al., this issue). There are different findings 
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regarding the association (or a lack of association) between the candidate genes, coding for the 
proteins involved in different biological systems, and risk for PTSD (Almli et al., 2014; Digangi et al., 
2013; Solovieff et al., 2014; Ryan et al., 2016). However, most of the data confirm hypothesized 
biological underpinnings of PTSD, showing risk gene variants in the serotonergic, dopaminergic, and 
GABA systems, immune system, HPA axis, neuropeptide Y, BDNF, apolipoprotein E, and other genes 
related to response to stress, fear, startle, cognition and anxiety (Nedic Erjavec et al., 2018; Ryan et 
al., 2016). Complex gene and environment interactions further complicate the understanding of the 
PTSD etiology, and it has been suggested that vulnerability to develop PTSD after traumatic experience 
results from numerous, independent gene x environmental interactions (Ryan et al., 2016). Candidate 
genes investigated in genetic or epigenetic studies of PTSD included genes for dopamine receptors 
type 2 and 4, dopamine transporter, catechol-o-methyl transferase, dopamine-beta-hydroxylase, 
ankyrin repeat and kinase domain containing 1, for serotonin receptor type 2A and serotonin 
transporter, for CRH receptor type 1, glucocorticoid receptor and FK506 binding protein 5, for BDNF, 
apolipoprotein E, pituitary adenylate cyclase-activating polypeptide type I receptor, cannabinoid 
receptor, C-reactive protein, mannosidase alpha class 2C member 1, opioid receptor-like 1, protein 
kinase C alpha and spindle and kinetochore-associated complex subunit 2, and many others (Ryan et 
al., 2016). Genome wide association studies (GWAS) offered a great number of novel loci and novel 
genes, but these variants are rarely replicated, or do not survive corrections for the genome-wide 
significance (Duncan et al., 2018).
Epigenetic changes can influence gene expression (Domschke, 2012; Ryan et al., 2016; Kim et al., 2017; 
Uddin et al., 2011), and therefore epigenetic research in PTSD (covered by Morrison et al., this issue) 
might provide an explanation how the environment affects or interacts with genes, making some 
individuals more vulnerable or resilient to develop PTSD after trauma exposure. Studies show that 
early childhood traumatic experience influences DNA methylation patters and people with PTSD show 
a unique DNA methylation signatures (Klengel et al., 2013). Therefore, improved knowledge on the 
genetic and epigenetic changes in PTSD might help in the early prediction of vulnerable individuals, 
offering possible targeted preventative interventions (Ryan et al., 2016). It has been proposed that 
PTSD is the result of the physiological adaptations affected by early life experiences, to allow survival 
after traumatic events (Yehuda and Seckl, 2011).
There is great heterogeneity in the biological (genetic and epigenetic) underpinning of PTSD as well as 
in the molecular architecture associated with vulnerability to development of PTSD after traumatic 
exposure. Due to this heterogeneity, there are few validated biomarkers for PTSD, and some proposed 
biomarkers (Zhang et al., 2011) still lack specificity and sensitivity. Biomarkers are non-invasive and 
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objective measures of patient diagnosis, prognosis, and treatment (Nikolac Perkovic et al., 2017). Some 
genetic or epigenetic marks might be used as early biomarkers to predict vulnerable individuals (Ryan 
et al., 2016). Theranostics is a discipline that combines diagnosis, prognosis, and therapy and offers 
targeted therapy based on specific analyses. Novel high throughput techniques and approaches called 
“omics” include information of the entire genome data (genomics), transcription products 
(transcriptomics), protein products (proteomics) and metabolic products (metabolomics) of an 
organism (Figure 1). “Omics” approach and high-throughput technologies enable the analyses of 
relationships, roles and mechanisms of action of various molecules, and provide better understanding 
of the normal physiological but also pathological processes and offer a new approach to explore 
various disorders and diseases. 
Therefore, a theranostic approach, combined with “omics” approaches, might improve the knowledge 
about the biological underpinning of PTSD, and offer novel diagnostic, prognostic, and therapeutic 
biomarkers and ultimately novel therapeutic strategies. There is a high priority for clearly defined and 
validated biomarkers, based on the “omics” approach. With these novel approaches, metabolomics 
and glycomics might also increase understanding of the biological alterations in PTSD. Studies using 
metabolomics and glycomics should more deeply investigate complex neurometabolic alterations in 
PTSD. These novel biomarkers should be used to discriminate between individuals who are vulnerable 
or resilient to development of PTSD, provide insights into the disease pathogenesis, and could be 
potentially used for development of targeted treatments and interventions. If identified early, 
vulnerable individuals exposed to trauma might receive appropriate psychological or pharmacological 
interventions prior the full development of PTSD (Ryan et al., 2016). 
2. Metabolomics
2.1.Metabolomic approaches
Metabolomics is a fast-developing scientific discipline and one of the analytical “omics” technologies 
with the most comprehensive approach (Figure 1), (Alonso et al., 2015; Kaddurah-Daouk and Krishnan, 
2009; Quinones and Kaddurah-Daouk, 2009; Wood, 2014). It seeks to study changes of an organism in 
a set of small molecules (metabolites) that are the final or intermediate products of biochemical 
processes driven by genetic regulation (Gonalez-Pena et al., 2015; Kaddurah-Daouk and Krishnan, 
2009; Mastrangelo et al., 2016; Quinones and Kaddurah-Daouk, 2009). Additionally, the metabolome, 
as a complex, large, and dynamic set of metabolites, can be affected by various exogenous and 
endogenous factors. Alternations in the metabolome might occur due to the dysfunction in metabolic 
pathways, or could represent adaptation mechanisms to some internal changes (physiological or 
pathological) or to external, environmental factors such as stress, nutrition, or drug administration 
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(Danielsson et al., 2012; German et al., 2008; Knee et al.,2013; Nedic Erjavec et al., 2018; Pontes et al., 
2017). 
Figure 1. “Omics” technologies: genomics, transcriptomics, proteomics, metabolomics
Several strategies, such as metabonomics, metabolomics, metabolic fingerprinting, metabolite 
profiling and target analysis are used. While metabolite profiling refers to quantification of previously 
identified metabolites, metabolomics is an unbiased approach. Metabolic fingerprinting provides 
classification, metabolite target analysis refers to quantification and qualitative analysis of specific 
metabolites, and metabonomics enables evaluation of altered metabolites due to treatment or disease 
(Dunn and Ellis, 2005). Metabolomics has a wide application in various scientific areas, such as zoology, 
botany, environment, pharmacology, nutrition, microbiology, toxicology, diagnostic, biomedicine and 
in many others (Alonso et al., 2015; Beckonert et al., 2007; Dunn et al., 2013; Pontes et al., 2017; Wu 
et al., 2008). In biomedicine, metabolomics plays an important role in identification and development 
of potential biomarkers for medical treatments and various diseases (Alonso et al., 2015; Danielsson 
et al., 2012). Analytical strategies applied in metabolomics can be classified into untargeted, semi-
targeted and targeted analyses. Usually studies start with an untargeted, non-hypothesis driven 
approach, which later helps to generate hypothesis for further targeted steps (Kaal and Janssen, 2008; 
Naz et al., 2014; Patti, 2011). In contrast to untargeted metabolomics, identities of metabolites in semi-
targeted and targeted metabolomics are known before data collection (Dunn et al., 2013; Patti, 2011). 
Therefore, targeted metabolomics provides absolute, while untargeted metabolomics reveals relative 
values (Wood, 2014). The workflow in a metabolomics study is summarized in Figure 2. Clear 
identification of the biological question will lead to the proper sample selection. Any type of biological 
matrix (biofluids, tissue, or cells) can be used in metabolomics with an adequate sample pretreatment 
(Gonzalez-Pena et al., 2016; Mastrangelo et al., 2016; Naz et al., 2013). The biofluids most frequently 
analyzed in metabolomics are saliva, serum, plasma, CSF, and urine (Cruickshank-Quinn et al., 2017; 
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Nedic Erjavec et al., 2018; Wood, 2014), whereas other biological materials include human cell lines, 
tissue biopsies, brain dialysates and blood cells (Wood, 2014). 
Figure 2. Metabolomics workflow
Sample preparation always starts with deproteinization and depends on the type of the separation 
technique applied. The selection of the analytical technique or set of techniques is based on the 
availability of the instrumentation, amount (volume) of sample, time and financial resources, as well 
as to the study target and sample type. After getting the global profile of the samples, profiles are 
overlaid, univariate and multivariate statistics are applied, and the metabolites that are statistically 
different are identified. Finally, the metabolites altered by the condition or disease should be included 
in biochemical pathways and their changes explained based on previous knowledge. When the 
potential biomarker is proposed as a diagnostic marker, it should be validated in a relevant cohort and 
with an ad hoc technique (Gonzalez-Pena et al., 2016; Mastrangelo et al., 2016; Naz et al., 2013). The 
study of metabolome is very complex from an analytical point of view, due to the variability of physico-
chemical properties and ranges of concentrations that metabolites exhibit. Polarities can include small 
ionic compounds, such as oxalate, or non-polar lipids as triglycerides and concentration ranges 
between molar and picomolar. For that reason, one single analytical technique does not suffice to 
obtain all the information (Gonzalez-Pena et al., 2016; Mastrangelo et al., 2016; Naz et al., 2013). Two 
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groups of techniques have been classically used: 1) Hydrogen-Nuclear Magnetic Resonance (HNMR), 
which is robust but with low sensitivity 2) Mass spectrometry (MS), with high sensitivity but low 
robustness, which is usually coupled to a separation technique such as liquid chromatography (LC), gas 
chromatography (GC), and/or capillary electrophoresis (CE). In addition to concentration and 
quantification, one-dimensional NMR (1D-NMR), which is commonly used, as well as two-dimensional 
NMR (2D-NMR), provide information about chemical structure (Alonso et al., 2015). 
2.2.Metabolomic findings in patients with PTSD
Only a few studies have examined the metabolome in PTSD and compared these metabolite data to 
control subjects (reviewed in Mellon et al., 2018; and Nedic Erjavec et al., 2018). Some studies reported 
possible associations between PTSD and gut microbiome, visceral adipose tissue and sympatho-
medullary-adrenal activity, but more research is necessary for better understanding of these findings 
(Hemmings et al., 2017; Mellon et al., 2018; Pace and Heim, 2011). Lower N-acetylaspartate/creatine 
ratio was found in the anterior cingulate region of 11 children and adolescents with PTSD who were 
maltreated, compared with 11 healthy matched subjects (De Bellis et al., 2000), but a small sample 
size, the use of a single voxel proton magnetic resonance spectroscopy, tissue heterogeneity within 
the voxel, and a lack of absolute quantification of metabolite measurements limited the significance 
of this finding. In the first study evaluating metabolites in adult patients with PTSD, which included 20 
PTSD participants and 18 healthy controls, 20 metabolites were identified as potentially associated 
with psychopathological alterations in PTSD (Karabatsiakis et al., 2015). These metabolites, based on 
their structure and function, can be divided into six categories: monosaccharides, nucleosides, fatty 
acid metabolites, glycerophospholipids, bile acids, and antioxidants (Karabatsiakis et al., 2015). 
However, both the multivariate and the univariate analysis in the study Karabatsiakis et al. (2015) 
revealed palmitoylethanolamide (PEA) and glycerophosphoethanolamine PE(17:1(9Z)/18:0) as the 
strongest candidates for involvement in PTSD. Clinical studies revealed the importance of 
endocannabinoid and glycerophospholipid pathways in PTSD patients, while altered metabolites in 
PTSD were associated with carbohydrate, lipid and amino acid metabolism, especially with glucose 
metabolism, i.e. citric acid cycle (Karabatsiakis et al., 2015; Mellon et al., 2018). In addition, plasma 
saturated and unsaturated fatty acids were altered in PTSD patients. Fatty acids such as linolenate, 
linoleate, docosahexaenoate (DHA), eicosapentaenoate (EPA) and docosapentaenoate (DPA), which 
have an important role in neuroprotection, were decreased in the plasma of subjects with PTSD 
(Mellon et al., 2018). Lower levels of DHA, vaccenic acid and eicosatrienoic acid, but higher levels of 
erucic acid were found in erythrocytes of 49 patients with civilian trauma-related PTSD when 
compared to 46 control subjects (de Vries et al., 2016). However, after adjusting for sociodemographic 
and dietary factors, only changes in DHA levels (i.e. lower levels in PTSD patients vs. controls) and 
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erucic acid levels (i.e. higher levels in PTSD patients vs. controls) were significant (de Vries et al., 2016). 
The metabolite differences between PTSD patients and control subjects can result from mitochondrial 
dysfunction, alterations in diet, microbial antigens or metabolism, inflammation and energy 
metabolism (Mellon et al., 2018). Among antioxidants, pantothenic acid (vitamin B5), which plays an 
important role in protecting against oxidative stress, was down-regulated in PTSD (Karabatsiakis et al., 
2015). Oxidative stress, defined as a metabolic imbalance between anti- and pro-oxidants generating 
excessive amounts of reactive oxygen species (ROS) (Cipak et al., 2008), is suggested to be 
bidirectionally associated with PTSD (Miller and Sadeh, 2014). In the case of lipid peroxidation, reactive 
aldehydes are generated, which are known to act as “second messengers of free radicals” for long 
periods and are effective on humoral, systemic levels (Gveric-Ahmetasevic et al., 2009; Sredoja-Tisma 
et al., 2009). 4-hydroxynonenal and related aldehydes are acting as bioactive markers of oxidative 
stress involved in the pathology of major human diseases, including metabolic and neurodegenerative 
disorders (Borovic Sunjic et al., 2005; Weber et al., 2013; Zarkovic et al., 2006; 2017). Their associations 
with PTSD are currently studied by metabolomics complemented by specific immunochemical 
methods (Fedorova and Zarkovic, 2017; Nedic Erjavec et al., 2018). In line with the assumption that 
oxidative stress and pro-inflammatory signaling pathways are affected or initiated by stress or trauma 
(Miller and Sadeh, 2014) are also findings of lipid peroxidation involvement in generalized anxiety 
disorder and of decreased antioxidant capacities in panic disorder (Bulut et al., 2013; Ozdemir et al., 
2012).  In addition to these metabolites, nitrogen monoxide (NO) plays different physiologically 
significant roles, including regulation of stress response, acting both as reactive oxygen and nitrogen 
species. Abnormalities in metabolism of NO are observed both in PTSD and in acute stress disorder 
(Bersani et al., 2016; Yeh et al., 2002). As NO is associated with inflammation processes and PTSD, 
global arginine bioavailability ratio (GABR) (GABR = arginine/citrullin + ornithine) has been determined, 
which represents the capacity for NO synthesis (Bersani et al., 2016). The study reported that PTSD 
subjects had increased levels of TNF-α, CRP, IL-6, and ornithine, as well as decreased levels of arginine, 
while citrullin did not differ between PTSD and control subjects; i.e. GABR value was decreased in PTSD 
patients compared to values in healthy controls (Bersani et al., 2016). However, comorbid depression 
and antidepressants could affect these GABR findings in PTSD subjects (Bersani et al., 2016). Moreover, 
choline levels were unchanged, whereas N-acetylaspartate (NAA) and creatine levels were decreased, 
in hippocampus of PTSD patients compared to levels in healthy controls (Schuff et al., 2001). A lower 
ratio of NAA and creatine was also detected in adolescents and children with PTSD (De Bellis et al., 
2000). However, alcohol abuse and metabolic and oxidative impairments might be partially 
responsible for the observed reductions (De Bellis et al., 2000; Schuff et al., 2001). 
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A small number of studies evaluated differences in particular metabolites in subjects with PTSD and 
healthy control subjects, and these findings suggest that some metabolomics markers, as well as some 
markers of oxidative stress, could be associated with particular mechanisms of PTSD. One can 
speculate that observed differences in metabolites between PTSD patients and healthy controls could 
also be the result of the suboptimal adaptation to changed environmental circumstances, such as 
trauma exposure. In order to suggest more concrete conclusions about the direct association between 
metabolites and mechanisms included in the etiology of PTSD, more studies should be conducted, 
confirmed, and replicated in larger groups of subjects with PTSD. 
2.3.Metabolomic findings in animal models of PTSD
In addition to human subjects, animal models with PTSD-like features are also used in metabolomic 
studies. Although animal models cannot completely replicate the processes, genetic regulation, and 
characteristic symptoms in humans, they can be a valuable tool to understand altered metabolic 
pathways and brain circuits, and could be used to develop potential biomarkers and pharmaceuticals 
(Kao, 2015). Development of PTSD-like symptoms in animal models can be modelled with various 
stressors, such as early life stress, physical, psychogenic, and psychosocial stress (Kao, 2015). In animal 
models of PTSD induced by a single prolonged stress, behaviors related to anxiety and elevated fear 
learning were accompanied by elevated oxidative stress and neuroinflammation, expressed as 
increased levels of malondialdehyde, IL-6, hippocampal nicotinamide adenosine dinucleotide 
phosphate oxidase 2 (NOX2), and 4-hydroxynonenal, as well as decreased density of hippocampal 
parvalbumin interneurons (Liu et al., 2016). In a predator stress paradigm, another putative animal 
model of PTSD, increased concentrations of ROS and pro-inflammatory cytokines were found (Wilson 
et al., 2013). C57BL/6 strain mice repeatedly exposed to a trained aggressor mouse of a different strain 
were used as an animal model with PTSD features, by applying a modified, resident-intruder, social 
defeat paradigm. Subject mice first showed effects relevant to acute stress disorder, such as gaining 
body weight and developing inflammation, and after 1.5 and 6 weeks of stress showed behaviors 
similar to PTSD symptoms (Gautam et al., 2015). The study demonstrated that a long stressful period 
of 5 days’ duration caused alterations in 40 metabolites measured in plasma after 24 hours and 14 
metabolites measured after 1.5 weeks. Similarly, after 10 days long stressful period, 20 metabolites in 
plasma were altered at 4 weeks and 37 metabolites were changed at 24 hours (Gautam et al., 2015). 
The finding that more mice subjected to a 10-day stress protocol had less alterations in metabolites, 
suggests that mice adapt to stressors and their metabolite levels normalize over time. In addition, gut 
microbiota derived metabolites (hippurate, phenylpropionylglycine and 3-phenylpropionate) were 
increased after chronic and acute stress protocols in aggressor-exposed mice (Gautam et al., 2015). 
However, metabolites in plasma, including lipids, carbohydrates and amino acids, differed between 
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acute and chronic stress protocols. Carbohydrate metabolite levels were elevated after acute protocols 
but reduced following withdrawal from stress. In addition to carbohydrates, groups subjected to 5- 
and 10-day stress protocols showed differences in amino acid levels, whereas lipid metabolites were 
increased at all-time points (Gautam et al., 2015). Acute alternations observed in this animal model of 
PTSD included inflammation, altered plasma metabolite levels and tissue damage, while chronic 
changes included altered metabolite levels, activation of lipid metabolism, hyperlipidemia and 
changed gene expression (Gautam et al., 2015). Moreover, mitochondrial dysfunction, upregulation of 
35 mitochondrial genes and altered fatty acid metabolism were observed in mice exposed to stress 
(Mellon et al., 2018; Zhang et al., 2015). Metabolomics of microdialysates from mouse brains revealed 
an association between basal metabolites in the prefrontal cortex and fear associated with foot shock 
stress (Kao et al., 2015). Metabolites, such as sarcosine, nicotinate, kynurenic and xanthurenic acid 
were associated with behavioral changes in this mouse model of PTSD (Kao et al., 2015). Twenty-eight 
days after the foot shock, prolonged fluoxetine treatment reduced PTSD-like behaviors and alterations 
in nucleus accumbens and anterior cingulate cortex of mice, by affecting metabolic pathways involved 
in energy metabolism (Kao et al., 2016). Additionally, a trend in citric acid cycle downregulation was 
observed, while metabolites like succinic, isocitric, citric, aconitic and oxalacetic acids were decreased 
in nucleus accumbens of shocked mice. In anterior cingulate cortex of foot-shocked mice, metabolites 
such as succinic, oxolutaric and oxalacetic acid were increased, whereas aconitic, isocitric, citric and 
pyruvic acids were decreased (Kao et al., 2016). Another metabolomic study in mice and hamsters was 
performed in order to determine possible metabolite differences between animals resistant and 
susceptible to development of PTSD-like behaviors (Dulka et al., 2017). Amino acids such as cystine, 
fumarate, and methionine were elevated in the nucleus accumbens of resistant compared to 
susceptible mice, while in hamsters, fumarate levels were increased in dominant compared to 
subordinate animals. On the other hand, susceptible mice had elevated GABA levels in hippocampus, 
whereas dominant hamsters had elevated tyrosine levels in ventromedial prefrontal cortex and lower 
serotonin levels in basolateral/central amygdala. Elevated levels of ATP products were also observed 
in ventromedial prefrontal cortex of resistant mice (Dulka et al., 2017). In a rat model of chronic 
unpredictable mild stress, susceptible and resilient rats exposed to stress had different metabolite 
levels and significantly decreased body weight compared to control rats (Li et al., 2017). The reduction 
in sucrose preference was observed in susceptible rats, but not among resilient rats when compared 
to control animals. Adenosine, creatinine, stigmasterol, serotonin, oleic acid, β and γ-tocopherol, 4,5-
dimethyl-2,6 dihydroxypyrimidine, N-acetyl-glucosamine and myo-inositol were increased, while 
metabolites like glycine, malic and dehydroascorbic acid, ornithine, L-lysine and L-glutamic, were 
decreased in resilient compared to control rats (Li et al., 2017). Components of citric acid cycle, such 
as pyruvate, malic, citric, fumaric and lactic acid were decreased, whereas cysteine, xanthine, aspartic 
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acid and lanosterol were elevated in resilient rats (Li et al., 2017). However, only malic acid presented 
a resilient- specific metabolite. In line with decreased levels of amino acid ornithine in resilient group 
of rats (Li et al., 2017), increased ornithine levels were found in plasma of PTSD-like subjects (Bersani 
et al., 2016), suggesting an important role of ornithine and arginine, as a components of urea cycle, in 
resilience to PTSD.
In summary, the presented findings reveal significant stress-induced changes in metabolome in animal 
models. According to the results of several above mentioned studies, the affected metabolic pathways 
include different processes such as (neuro-) inflammation, auto-immune reactions, oxidative stress, 
and energy metabolism. These results further underscore the complex etiology of PTSD, as well as the 
fact that PTSD is a neuropsychiatric disorder with systemic effects. Of course, further studies are 
needed to clarify the biological underpinnings of PTSD.
3. Glycomics
3.1. Glycomic approach
Glycans are oligosaccharide chains covalently attached to biomacromolecules such as proteins and 
lipids which can significantly alter their physiochemical properties and consequently their biological 
role (Varki A, 1993). Glycomics is an “omics” approach technology that determines all glycans released 
from glycoproteins (Miura and Endo, 2016) and represents the systematic study of the glycome, a 
complete repertoire of glycan structures with their functional roles in biological systems (i.e. in cells, 
tissues or organisms), which can be observed under specific conditions such as time, location and 
environment. Each organism and even each cell type has its own distinct glycome, determined by both 
genetic and environmental factors, although its size is yet unknown. The great diversity and dynamics 
of the glycome during development as well as in various conditions and disorders, suggests that glycans 
should be studied in whole by using glycomics (Rudd et al., 2017). In complex organisms, glycans play 
an important role in virtually all processes that involve more than a single cell (National Research 
Council, 2012). The glycan parts of (glyco)proteins are integral elements of the final molecular 
structure and together with amino acids in the polypeptide backbone form a single molecular entity 
that performs biological functions. The majority of membrane and secreted proteins are post-
translationally modified by covalent addition of glycans with very high site occupancy, thus changes in 
glycosylation of cell membrane receptors in response to external or internal stimuli, can drastically 
change their affinity to target molecules or cells (Zielinska et al., 2010) and in this manner participate 
in cell signaling, migration, angiogenesis and development (Ohtsubo and Marth, 2006). However, 
glycans generally do not turn physiologic processes on and off, but rather modify the behavior of the 
cell by responding to internal or external stimuli. This is particularly seen in immunological system 
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where glycans play a role in leukocyte migration (Mitoma et al., 2007), antibody-dependent 
cytotoxicity (ADCC) (Masuda et al., 2007) and pathogen-host interactions (Ilver et al., 1998). For 
example, glycans attached to immunoglobulin G (IgG) have very profound effects on protein structure 
(Subedi and Barb, 2015) and alternative glycosylation (attachment of different glycans) affects binding 
of IgG to all Fc receptors and is in this way analogous to variation in protein sequence due to genetic 
variations (Subedi and Barb, 2016). Glycans contribute to both structure and function of glycoproteins, 
but, contrary to the polypeptide part that is directly encoded in the genome, glycan parts of 
glycoproteins do not have a direct genetic template (Kristic et al., 2014). Instead, final glycan structures 
are determined through dynamic interactions between hundreds of proteins and small molecules that 
form the complex pathway of glycan biosynthesis (Shen et al., 2017). Namely, glycans are shaped by 
fine-tuning of genetic variations, epigenetic and gene expression regulation, post-translational 
modifications, and activity of corresponding proteins (Gornik et al., 2012). The majority of glycosylation 
processes occurs in the endoplasmic reticulum and Golgi apparatus and involves many different 
enzymes such as glycosyltransferases, glycosidases and transporters, transcriptional factors, and other 
proteins (Moremen et al., 2012). The major types of glycans present in mammals, N-glycans, O-glycans, 
glycosphingolipids and glycosaminoglycans, are very heterogeneous as they differ in size, charge, 
occurrence, and complexity (Moremen et al., 2012). Enormous variability of glycan determinants 
results from different number, order, and type of sugar monomers, diverse in their numeric 
configuration, position, and branching at protein multiple sites (Cummings, 2009). In addition, protein 
glycosylation is tissue-specific and therefore glycoproteins in distant tissues, although sharing the same 
protein sequence, might differ in glycan profile (Almeida and Kolarich, 2016). Free glycans or glycans 
that are part of glycoproteins or glycolipids bind to glycan receptors - lectins. In animals, major classes 
of lectins based on their amino acid sequences and biochemical properties, are C­type lectins such as 
selectins, collectins and endocytic lectins, and S­type lectins such as galectins (Ghazarian et al., 2011). 
Lectin–glycan interactions are crucial for various physiological as well as pathological processes (Kletter 
et al., 2013). The most common protein glycosylation is N-glycosylation, and its absence is 
embryonically lethal (Marek et al., 1999), whereas mutations that obstruct proper glycosylation cause 
debilitating diseases (Freeze, 2006). Variations in genes have been found to be associated with changes 
in glycosylation (Hennet, 2012; Huffman et al., 2011; Lauc et al., 2010), whereas epigenetic regulation 
of some genes was also found to affect protein glycosylation (Zoldos et al., 2012). After the initial 
discovery of altered IgG glycosylation in rheumatoid arthritis (Parekh et al., 1985), hundreds of studies 
demonstrated altered glycosylation in different diseases. Inter-individual differences in glycosylation 
are important and associated with predisposition and course of numerous diseases, such as congenital, 
immunological and infectious disorders, cardiovascular and neurodegenerative diseases, cancer, and 
diabetes. (Lauc et al., 2016). However, the functional relevance of differences in glycosylation found in 
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disease compared with healthy states and mechanisms underlying these differences are still 
insufficiently understood (Lauc et al., 2016). As glycans integrate genetic and environmental factors, 
they are more closely associated with complex diseases than sequence variations in the genome 
(Zoldos et al., 2013). Glycosylation reflects the biological state of an organism and hence represents a 
potential biomarker for disease susceptibility and its course, as well as to treatment response (Lauc et 
al., 2016). Therefore, no biological analysis at systems level is complete without investigating the 
glycome in addition to the genome, transcriptome, proteome and metabolome. However, due to 
glycan complexity and methodological issues, glycomics has been falling behind genomics and 
proteomics, and in comparison to proteins and genes, fewer techniques have been available for glycan 
analysis (Sato, 2016). 
Recently, various techniques have been developed for studying the glycome at different levels (Hart 
and Copeland, 2010). A number of high-resolution and sensitive techniques are available today for 
glycan research, such as CE, high performance liquid chromatography (HPLC), MS and lectin 
microarrays (Hart and Copeland, 2010). In addition, a variety of high-throughput approaches for glycan 
analysis are currently in use including ultra-performance liquid chromatography with fluorescence 
detection (UPLC-FLR), liquid chromatography electrospray mass spectrometry (LC-ESI-MS), capillary 
gel electrophoresis with laser induced fluorescence detection (CGE-LIF), matrix assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), nano-liquid 
chromatography coupled to tandem mass spectrometry (nano-LC MS/MS) and liquid chromatography 
triple quadrupole mass spectrometry with multiple reaction monitoring (LC-QqQ-MS with MRM) 
(Trbojevic-Akmacic et al., 2016). Glycans can be obtained from cell lysates, homogenized tissue, 
enriched membranes, as well as from different body fluids such as serum/plasma, urine, saliva, tears, 
milk, semen or amniotic fluid, but most analytical methods provide relative rather than absolute 
quantification of glycans in a sample (Etxebarria and Reichardt, 2016). In general, glycans are first 
enzymatically or chemically released from glycoproteins, then separated using different stationary 
phases and finally detected (Figure 3). Labelling or chemical modification of released glycans is 
performed in order to optimize HPLC and CE, and improve MS detection employing linkage-specific 
glycosidases and/or the use of glycan standards.
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Figure 3. Glycomics workflow
A combination of approaches is usually applied, investigating the individual glycan repertoire as well 
as performing global glycan analysis (Rudd et al., 2017). Basic classes of glycomic analyses are 
glycoprofiling, glycan class characterization, and full structural analysis, each providing specific 
information. Glycoprofiling is one-dimensional separation used to obtain a signature of the glycome 
profile by applying methods such as HPLC, CE and MS. Glycan class characterization uses technologies 
such as weak anion-exchange (WAX) HPLC and MS to separate glycan mixtures into different glycan 
types and to provide their relative quantification. Detailed (full) structural analysis determinates 
monosaccharide sequence and modifications, anomericity, and linkage of the glycans in a glycome, 
using HILIC separation and MS. All of these glycomic approaches produce high quantities of data that 
need to be analyzed. Although progress in bioinformatics and databases for major analytical platforms 
used in glycan research has recently been accelerating, it is still at the beginning compared to genomics 
and proteomics (Aoki-Kinoshita, 2008). Therefore, the development of bioinformatic analysis tools 
such as algorithms to support the characterization of glycan structures for high-throughput 
applications, as well as generation of databases containing well-structured glyco-related data, will 
foster the integration of glycobiology into all fields of biomedical science.
3.2. Glycomic findings in human subjects with PTSD
While significant changes of N-glycome were found in several psychiatric and neurodegenerative 
disorders, such as schizophrenia (Bauer et al., 2010; Stanta et al., 2010), major depressive disorder 
(Park et al., 2018), attention-deficit hyperactivity disorder (Pivac et al., 2011), dementia (Vanhooren et 
al., 2010) and Alzheimer’s disease (Lundström et al., 2014), studies of N-glycosylation in PTSD are 
scarce. One small study (Moreno-Villanueva et al., 2013) involving 13 individuals with PTSD, 9 trauma-
exposed (high-stress) subjects and 10 subjects exposed to low-stress, measured nine plasma N-glycan 
structures in association with traumatic load and stress exposure. It has been previously shown that a 
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GlycoAge Test, the logarithmic ratio of two N-glycan structures, agalactosylated core-a-1,6-fucosylated 
biantennary N-glycan (FA2), whose concentration grows with aging, and bigalactosylated core-a-1,6-
fucosylated biantennary (FA2G2), whose concentration decreases in older age, can be used as a 
predictor of biological age (Pucic et al., 2011; Vanhooren et al., 2007; 2010). In this study, subjects with 
PTSD and higher traumatic load had a significantly higher GlycoAge index compared to low stress group 
and this effect correlated with the amount of stress an individual experienced (Moreno-Villanueva et 
al., 2013). The presented results suggested accelerated aging in PTSD subjects in comparison to age-
matched healthy individuals (Moreno-Villanueva et al., 2013), supporting findings using GlycoAgeTest 
in patients with dementia or Cockayne syndrome, involving neurodegeneration and premature ageing 
(Vanhooren et al., 2010). In patients with PTSD (Moreno-Villanueva et al., 2013), decreased bigalacto 
core-1,6-fucosylated bisecting biantennary glycans (FA2B2G2) and increased agalacto core-1,6-
fucosylated bisecting biantennary glycans (FA2B) were detected. FA2B2G2 glycans, which are reduced 
in PTSD, are also lower in patients with hepatocellular cancer (Liu et al., 2007) and in patients within 
24 hours of having major abdominal surgery (Gudelj et al., 2016). On the other hand, increased 
biantennary glycans (FA2B) in PTSD are usually found to be elevated in older age. As older age and 
PTSD are frequently associated with inflammation, these findings suggest that subjects with PTSD have 
higher markers of inflammation and older age, although tri- and tetra-antennary sialyted, and not 
biantennary glycans, are found to be increased in various inflammatory process (Gudelj et al., 2016). 
The discrepancies might be explained with the lower resolution of N-glycan determination and/or the 
small number of subjects included in the above PTSD study (Moreno-Villanueva et al., 2013). 
Both acute and chronic stress increase the risk of immune system dysregulation, and this is particularly 
seen in individuals suffering from PTSD (Boscarino, 2004; Glaesmer et al., 2011; Mellon et al., 2018; 
Pacella et al, 2013), and PTSD patients are more prone to development of autoimmune (O'Donovan et 
al., 2015) and inflammatory diseases (Boscarno, 2004; Lindqvist et al., 2014; Wang et al., 2017). Some 
studies have also shown that antennary fucosylation with increased number of antennas and sialic acid 
residues, as well as smaller numbers of added galactoses on IgG bound N-glycans, which is 
characteristic of acute and chronic inflammation, and observed in patients with rheumatoid arthritis 
(Arnold et al., 2008; Reiding et al., 2017). Tri- and tetra-antennary sialyted plasma glycans are usually 
increased in inflammatory processes (Gudelj et al., 2016), whereas a lack of core fucose on IgG 
drastically increases antibody-dependent cellular cytotoxicity (Masuda et al., 2007). Therefore, strong 
connections between PTSD and inflammatory processes are evident; however, their underlying 
mechanisms and associations with changes in N-glycome are still uncertain. Higher number of subjects 
with PTSD and more precise determination of glycans are necessary to provide more definitive 
conclusions on whether and how the glycosylation patterns mediate PTSD symptomatology. The 
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possible biological mechanisms involved in PTSD include cytokine disbalance (Wang et al., 2017) and 
changes in proportion of naïve, cytotoxic and memory T-lymphocytes (Sommershof et al., 2009), which 
follow the pattern of T-cells distribution in older age individuals (Shen et al., 1999). It has been shown 
that individuals with PTSD have elevated proinflammatory cytokines such as IL-1, IL-6 and IFN- 
(Wang et al., 2017), as well as significantly higher ”pro-inflammatory score” (Lindqvist et al., 2014). 
Elevated peripheral inflammatory cytokines could trigger neuroinflammation, by crossing the blood-
brain barrier and causing the inhibition of neurogenesis and death of dopaminergic neurons (de Pablos 
et al., 2014), consequently leading to characteristic PTSD symptoms (Muhie et al., 2017). Other 
potential contributors to PTSD symptomatology are metabolic syndrome, insulin resistance (Heni et 
al., 2015) and mitochondrial damage (Naviaux, 2014; Picca et al., 2017; Zhang et al., 2016), which are 
all commonly present in subjects with PTSD. Namely, patients with PTSD more often develop metabolic 
diseases, such as diabetes and metabolic syndrome (Blessing et al., 2017; Michopoulos et al., 2016). 
On the other hand, changes in glycosylation patterns were also reported in people with increased body 
mass index (BMI) (Nikolac-Perkovic et al., 2014) and diabetes (Lemmers et al., 2017). 
There are only a few reports of the observed differences in glycosylation profile in sera of highly 
stressed individuals who experienced imprisonment in war camps (Barisic et al., 1996) and professional 
soldiers (Flögel et al., 1996; Lauc et al., 1998), but these subjects did not have a diagnosis of PTSD. In 
these studies, the N-glycosylation profile was determined by Western blot using five digoxigenin-
labelled lectins isolated from plants, each with specificity for different glycosidic bonds. Significantly 
higher concentrations of 57 kDa glycoprotein (subsequently named stressin) in sera of war prisoners 
(Barisic et al., 1996) and soldiers (Flögel et al., 1996) was found in comparison to control subjects. The 
authors concluded that concentrations of this glycoprotein could be positively correlated with stress 
intensity. Additional analysis (Lauc et al., 1998) showed that N-oligosaccharides, mostly sialic acid, 
contributed to more than 40% of the total mass of this highly glycosylated protein, in agreement with 
more recent experiments showing higher sialylation of proteins in inflammatory processes (Gudelj et 
al., 2016). 
These findings of altered particular glycans in acutely stressed, traumatized individuals and subjects 
with disorders of the central nervous system (Barone et al., 2012) and PTSD (Moreno-Villanueva et al., 
2013) suggest that stress-related disorders might be affected or mediated by changes in crucial N-
glycan patterns on immunoglobulins and immune cells receptors. However, these results should be 
validated and replicated using larger samples. 
21
3.3. Glycomic findings in animal models of stress
There is no information on glycosylation pattern in animal models of PTSD, however there are few 
studies on stressed animals. Although in these studies, the animals were exposed to some traumatic 
events or acute and chronic stress conditions, no behaviors corresponding to PTSD symptoms in 
humans were measured. The first studies of glycosylation in animal models of stress were conducted 
by Tsukada et al. (1989) and Kitajima et al. (1990), who investigated changes in glycosylation patterns 
of gastric mucosa in rats. They observed that rats exposed to traumatic events had a significantly lower 
percentage of N-acetylgalactosamine incorporation in gastric proteins than control animals (Tsukada 
et al., 1989), as well as changes in binding of several lectins to gastric mucosa proteins such as peanut 
agglutinin (PNA) lectin, specifically binding galactose (Kitajima et al., 1990). More recent experiments 
studied glycosylation patterns in Atlantic salmon (Salmo salar L.) exposed to long-term stress 
conditions (Liu et al., 2008). This study used MS analysis to monitor intact glycan serum O-acetylation 
of glycoprotein bound sialic acid (Liu et al., 2008), the most common modification of sialic acid (Klein 
and Roussel, 1998). O-acetylated sialic acids could partly regulate virus binding, cell signaling and 
intercellular interaction, cancer progression, immune system regulation, lectin recognition, as well as 
gene expression (Corfield et al., 1999; Ghosh et al., 2005; Schauer et al., 2000; Shen et al., 2004; Severi 
et al., 2007; Sjoberg et al., 1994). Previous studies also identified di-O-acetylation of sialic acid as a 
major modification of N-glycans in fish serum (Ylonen et al., 2001; 2002). Liu et al. (2008) observed 
that a major glycoform in salmon sera was monoacetylated sialic acid, which decreased after two 
weeks’ exposure to a stressor, while di-O-acetylated sialic acid significantly increased in comparison to 
the stress-free fish. After 4 weeks, levels of mono- and di-O-acetylated sialic acids returned to the 
baseline levels, indicating a possible role of this sialic acid derivative in maintenance of organism 
homeostasis, adaptation to environmental stress and monitoring of biological response to short- and 
long-term stress (Liu et al., 2008). However, to our knowledge, there are still no studies showing N-
glycosylation patterns in animal models of PTSD, which might elucidate major glycan differences 
between acutely and chronically stressed or between traumatized vs. non-traumatized animals. 
4. Conclusion
To the best of our knowledge, only a few studies evaluated metabolomic and glycomic profiling in 
patients with PTSD (Table 1). Since these studies included a small number of patients (De Bellis et al., 
2000; de Vries et al., 2016; Karabatsiakis et al., 2015; Moreno-Villanueva et al., 2013), further studies 
with larger groups of patients with PTSD, and replications are needed to confirm or to reject the 
proposed conclusions. Stress exposure can considerably compromise the immune system and 
accelerate cellular aging, which can be seen as alterations in the N-glycan profile and in the 
metabolome of animals or humans. The findings from the literature indicate possible roles of altered 
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metabolome and changes in N-glycosylation as biomarkers or mediators of acute stress and PTSD, as 
well as potential targets enabling personalized medicine for PTSD or other diseases. The advances in 
“omics” technologies, especially in metabolomics and glycomics, combined with other “omics” 
approaches, might be used to improve the understanding of the molecular, cellular, and circuit basis 
of biological underpinning of PTSD (Nievergelt et al., 2018). “Omics” based biomarkers will play a major 
role in identification, characterization, and understanding of PTSD, offering new knowledge that would 
reveal impairments in metabolic and glycan pathways, metabolite levels, glycoproteins, biochemical 
processes and their complexity (Lauc et al., 2016; Miura and Endo, 2016; Patti et al., 2012; Zhang et 
al., 2012). The potential of glycan biomarkers lays in the fact that glycans and glycoproteins reflect the 
physiological and pathological conditions of individual patients (Lauc et al., 2016; Miura and Endo, 
2016). PTSD, like other neuropsychiatric disorders, is a complex polygenic disease and therefore 
multiple factors are involved in its progression and development. Previous studies have shown the 
importance of animal models with PTSD-like features in revealing altered metabolites and biochemical 
processes, which might offer insights into pathophysiology of PTSD and propose novel potential 
biomarkers (Dulka et al., 2017; Gautam et al., 2015; Kao et al., 2016), although glycomic studies on 
animal models of PTSD are missing to date. However, in addition to animal studies, clinical studies on 
human participants are necessary, because animal models cannot completely replicate some specific 
symptoms, emotions, and processes characteristic of humans exposed to traumatic events and their 
experience of the trauma. Therefore, both animal models and clinical metabolomic and glycomic 
studies and their integration with other “omics” technologies, like lipidomics, genomics, epigenomics, 
transcriptomics and proteomics will improve knowledge about PTSD and might provide insights into 
biological origin of PTSD, identify molecular targets responsible for the onset of PTSD after exposure 
to trauma, offer novel theranostic biomarkers and ultimately might provide novel therapeutic 
approaches (Girgenti et al., 2017; Lauc et al., 2016; Nedic Erjavec et al., 2018; Ryan et al., 2016; Wolf 
et al., 2016; Zhang et al., 2012). Here we have reviewed a few studies showing metabolomics and 
glycomics data in subjects with PTSD: at present, we cannot confirm whether these 
metabolic/glycomic changes are risk factors for PTSD or consequences of PTSD (Mellon et al., 2018). 
The presented data suggest that metabolomics and glycomics findings might be primarily used as 
diagnostic and prognostic markers. However, based on the integration of all novel “omics” approaches, 
further targeted mechanistic studies might provide insight into the possible therapeutic targets, and 
therefore metabolomic/glycomic studies in PTSD might offer theranostic applications.
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Table 1. Overview of significant findings in the field of metabolomics and glycomics in PTSD
Paper Subjects Sample type Method Main findings
Kao et al., 
2015
FS-induced mouse model of PTSD 







LC-MS Central metabolites included in citrate cycle, glyoxylate and 
dicarboxylate metabolisms correlated with the FS-related 
early changes in arousal. Xanthurenic acid, glucose-1-
phosphate, sarcosine and spermidine levels correlated with 
the FS-related longer-term PTSD-symptoms
Kao et al., 
2016
FS-induced mouse model of PTSD 
(exposed and non-exposed group; Ntotal=15)
Brain tissue 
punches




Mouse model exposed to a trained 
aggressor mouse and developing behavioral 
features of PTSD (8 groups: 
control/treatment, 5/10 weeks of treatment, 
sampling 24 hours/1.5 weeks/4 weeks after 
treatment; Ntotal = 40-48)
Blood plasma GC-MS
LC-MS
Gut-derived metabolites (3-phenylpropionate, 
phenylpropionylglycine, hippurate) altered acute and 
chronically. Metabolites of gut microbiota (2-4-
hydroxyphenyl propionate, indole lactate, phenyl lactate) 
elevated in treated mice. Carbohydrates, amino acids and 
lipids levels correlated with stressor duration and the length 
of stress-withdrawal period.
Karabatsi-
akis et al., 
2015
PTSD patients and healthy control subjects 
(Ntotal=38)
Blood serum LC-MS 13 metabolites (4 glycerophospholipids, 2 fatty acid 
metabolites, 2 nucleosides, 2 bile acids and derivates, 1 
monosaccharide, 1 anti-oxidant) significantly altered in 
PTSD patients; 12 metabolites correlated with PTSD 
symptoms determined according to CAPS scores.
De Bellis et 
al., 2000
Children and adolescents with PTSD and 







N-acetylaspartate to creatine ratio was lower in the 
maltreated children with PTSD.
de Vries et 
al., 2016




DHA was significantly lower in PTSD patients after 




Patients with PTSD, trauma-exposed 
patients and control subjects (Ntotal=32)
Blood plasma DSA-
FACE
Higher Glycoage test score in PTSD and trauma-exposed 
patients. Decreased FA2B2G2 in patients with PTSD. 
Increased FA2B in patients with PTSD.
NA-not available; LC-liquid chromatography; GC-gas chromatography; MS-mass spectrometry; FS-foot shock; NAc-nucleus accumbens; ACC-
anterior cingulate cortex; MRS-magnetic resonance spectroscopy; DHA- docosahexaenoic acid; DSA-FACE- DNA sequencer-assisted flurophore-
assisted carbohydrate electrophoresis; FA2B2G2-bigalacto core-1,6-fucosylated bisecting biantennary glycan; FA2B-agalacto core-1,6-fucosylated 
bisecting biantennary glycan; CAPS- clinician administrated PTSD scale
